Please enter your username and password below, if you are not yet a member of Oncology Central remember you can register for free.
Already have an account? Login here
Categories // Skin
Due to be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I (27–28 April 2020), an international team of researchers investigated whether an immune checkpoint inhibitor (ICI) combined with two targeted therapies could improve efficacy in BRAFV600 mutation-positive melanoma, compared with targeted therapy alone.
The Phase III trial (NCT02908672), termed IMspire150, included 514 treatment-naïve patients with unresectable Stage IIIc/IV melanoma, measurable disease by RECIST 1.1 and BRAFV600 mutations. Participants were randomized to one of two trial arms.
It's completely free
Written ByRachel Jenkins, Future Science Group
Updated 30 April, 2020